O'Neill Gilmore Neil 4
4 · Editas Medicine, Inc. · Filed Mar 4, 2026
Insider Transaction Report
Form 4
O'Neill Gilmore Neil
DirectorCEO
Transactions
- Sale
Common Stock
[F1][F2]2026-03-03$2.02/sh−5,394$10,894→ 263,693 total
Footnotes (2)
- [F1]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
- [F2]This transaction was executed in multiple trades at prices ranging from $2.0050 to $2.0204 The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Signature
/s/ Gilmore O'Neill|2026-03-04